Kazia Therapeutics Share Purchase Plan and Booklet

Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA) (Kazia or Company), an Australian oncology focused biotechnology company, is pleased to offer eligible Kazia shareholders in Australia and New Zealand the opportunity to participate in the Kazia Share Purchase Plan (SPP), as previously announced on Thursday, 18 October 2018.

The SPP is open to holders of fully paid ordinary shares in Kazia as at 7:00 pm (Sydney time) on the record date of Wednesday, 17 October 2018 and whose address on the share register is in Australia, New Zealand and the United Kingdom, provided that such shareholder is not in the United States nor a US person (as defined in Rule 902 under the US Securities Act of 1933) or a person acting for the account or benefit of a US person. The SPP is also being extended to eligible shareholders who are custodians, to participate in the SPP on behalf of certain eligible beneficiaries on the terms and conditions set out in the SPP booklet. The SPP will not be underwritten.

Full details of the SPP can be found within the SPP booklet. The SPP booklet and an application form are being mailed to eligible shareholders today.

Applications for shares under the SPP open Tuesday, 23 October 2018 and are expected to close at 5:00 pm (Sydney time) on Friday, 16 November 2018.

About Kazia Therapeutics Limited (ASX: KZA, NASDAQ: KZIA)

Kazia Therapeutics is an innovative oncology-focused biotechnology company, based in Sydney, Australia. Our pipeline includes two clinical stage drug development candidates, and we are working to develop therapies across a range of oncology indications.

Our lead program is GDC-0084, a small molecule inhibitor of the PI3K / AKT / mTOR pathway, which is being developed to treat glioblastoma multiforme, the most common and most aggressive form of primary brain cancer in adults. Licensed from Genentech in late 2016, GDC-0084 entered a phase II clinical trial in March 2018. Initial data is expected in early calendar 2019. GDC-0084 was granted orphan designation for glioblastoma by the US FDA in February 2018.

TRX-E-002-1 (Cantrixil), is a third generation benzopyran molecule with activity against cancer stem cells, and is being developed to treat ovarian cancer. TRX-E-002-1 is currently undergoing a phase I clinical trial in Australia and the United States. Initial data was presented in June 2018 and the study remains ongoing. Cantrixil was granted orphan designation for ovarian cancer by the US FDA in April 2015.

Register Interest